SignalChem’s Genomics-based Technology and ExpressPharming Expression Platform are designed to deliver a wide range of biopharmaceuticals in plants.

Genomics-based Technology to Enhance Bioactive Components


SLC1021, is a natural extract of lettuce rich in super polyphenols (chlorogenic acid, chicoric acid, quercetin derivatives, and anthocyanins), recently developed by SignalChem scientists.

This proprietary pure natural extract contains more than 20% polyphenols (w/w), has good antiviral and anti-inflammatory activities, and has extremely high antioxidant capacity and a series of metabolic correction activities.
These compounds may have a protective effect on viral infection, diabetes, cardiovascular disease, other diseases including memory and vision loss, inflammation and cancer.

Based our investigations and documented studies, SLC1021 is considered to have the potential to act against the novel coronavirus (SARS-CoV-2) by inhibition of 3C-like protease (3CLpro), RNA dependent polymerase (RdRp), and SARS-CoV-2 RNA helicase and triphosphatase (Nsp13).

ExpressPharming Expression Platforms to produce therapeutic proteins

Recombinant human serum albumin

Human serum albumin (HSA) plays an important role in maintaining plasma oncotic pressure and fluid balance between the body’s compartments. HSA is thus widely used in the clinic to treat diseases. The need for HSA for therapeutic applications is estimated to be more than 500ton worldwide. Commercial production is mostly based on fractionating human plasma HSA (pHSA). However, the shortage of and safety issues arising from using plasma underscore the importance of recombinant HSA (rHSA) as a promising substitute for pHSA. rHSA from plant cells exhibits great potential for more cost-effective products with no adverse effects, which will play a vital role in future human therapeutics.

Recombinant human growth factors

With an expanding clinical demand for functional therapeutic growth factor proteins, there is an increasing requirement for the massive production of bioactive recombinant human growth factors. Using the ExpressPharming platforms, SignalChem is producing growth factors such as human basic fibroblast growth factor (bFGF), human acidic fibroblast growth factor 1 (FGF-1), human epidermal growth factor (hEGF), nerve growth factor (NGF).

Recombinant protein vaccine candidates

SignalChem is developing strategies to produce recombinant protein vaccines and to enhance the immunogenicity and therapeutic potency, methods to increase vaccine-expressing, and challenges facing the production of vaccines in plants.

Recombinant angiotensin-converting enzyme 2 (ACE2) protein against SARS-CoV-2

The rapid global pandemic SARS-CoV-2 emphasizes the urgent need for the development of effective therapeutics that are affordable and scalable. Using ExpressPharming platforms can rapidly and effectively produce a functional ACE2 protein to provide an affordable therapeutic candidate against SARS-CoV-2.